The application for the renewal of the approval of the active substance cyantraniliprole was submitted on 8 September 2023 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 28 February 2024 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 26 June and 25 July 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 42 months, until 14 March 2030.
Recital 43, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026